Taysha Gene Therapies, Inc. (TSHA)

USD 1.83

(-9.85%)

Annual Income Statements

(In USD)
Breakdown 2023 2022 2021 2020 2019
Revenue 15.45 Million 2.5 Million - - -
Cost of Revenue 1.37 Million 2.48 Million 492 Thousand 9000.00 -
Gross Profit 14.08 Million 15 Thousand -492 Thousand -9000.00 -
Operating Expenses 87.89 Million 128.52 Million 173.26 Million 43 Million 1.11 Million
Selling, General and Administrative Expenses 30.04 Million 37.36 Million 41.32 Million 11.1 Million 128 Thousand
Research and Development Expenses 56.77 Million 91.16 Million 131.94 Million 31.89 Million 987 Thousand
Other Expenses 1.06 Million -18 Thousand - -17.03 Million -
Cost and Expenses 87.89 Million 128.52 Million 173.26 Million 43 Million 1.11 Million
Operating Income -72.43 Million -162.44 Million -173.26 Million -43 Million -1.11 Million
Interest Expense 4.99 Million 3.79 Million 1.42 Million 28 Thousand -
Income Tax Expense - 3.56 Million 936 Thousand -17.01 Million -4.46 Million
Earnings before Tax -111.56 Million -166.01 Million -174.52 Million -60.01 Million -1.11 Million
Net Income -111.56 Million -169.58 Million -175.45 Million -43 Million -1.11 Million
Earnings Per Share Basic -0.96 -3.86 -4.66 -2.43 -0.03
Earnings Per Share Diluted -0.96 -3.86 -4.66 -2.43 -0.03
Weighted Average Shares Outstanding 116.12 Million 43.95 Million 37.65 Million 17.66 Million 36.99 Million
Weighted Average Shares Outstanding (Diluted) 116.12 Million 43.95 Million 37.65 Million 17.66 Million 36.99 Million
Gross Margin 0.91 0.01 - - -
EBIT Margin -6.81 -50.28 - - -
Profit Margin -7.22 -67.78 - - -
EBITDA -105.19 Million -159.72 Million -172.77 Million -42.99 Million -
Earnings Before Tax Margin -4.69 -64.93 - - -

Income Statement Charts